Jim Simons Sage Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 513,300 shares of SAGE stock, worth $2.81 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

513,300

Previous 553,396 7.25%

Holding current value

$2.81 Million

Previous $6.01 Million 38.43%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$7.02 - $13.08 $281,473 - $524,455	-40,096 Reduced 7.25%	513,300 $3.7 Million
Q2 2024 Aug 09, 2024	BUY	$10.58 - $17.9 $5.48 Million - $9.28 Million	518,296 Added 1476.63%	553,396 $6.01 Million
Q1 2024 May 13, 2024	BUY	$18.62 - $26.95 $653,562 - $945,945	35,100 New	35,100 $658,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $1.43 Million - $4.19 Million	85,600 New	85,600 $1.76 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $990,996 - $1.33 Million	-30,700 Reduced 70.74%	12,700 $497,000
Q2 2022 Aug 12, 2022	BUY	$27.52 - $37.99 $1.19 Million - $1.65 Million	43,400 New	43,400 $1.4 Million
Q3 2020 Nov 13, 2020	SELL	$41.13 - $62.45 $11.8 Million - $17.8 Million	-285,800 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$25.95 - $43.15 $12 Million - $19.9 Million	-461,332 Reduced 61.75%	285,800 $11.9 Million
Q1 2020 May 14, 2020	BUY	$26.15 - $77.24 $16.6 Million - $49.2 Million	636,541 Added 575.58%	747,132 $21.5 Million
Q4 2019 Feb 13, 2020	BUY	$60.18 - $154.77 $6.66 Million - $17.1 Million	110,591 New	110,591 $7.98 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account